Biogen and Stoke Partner to Advance Dravet Syndrome Treatment

Biogen and Stoke Therapeutics have announced a strategic collaboration to advance the development and commercialization of zorevunersen, a promising investigational therapy for Dravet syndrome. This rare and severe genetic epilepsy has limited treatment options, leaving many patients and families without an effective disease-modifying therapy. Under the partnership, Biogen will oversee commercialization outside the U.S., Canada, and Mexico, while Stoke continues to lead global development efforts. With a Phase 3 registrational study set to begin in 2025, zorevunersen has the potential to bring long-awaited relief to those affected by Dravet syndrome.

This agreement strengthens Biogen’s position in neurology while providing Stoke with the financial backing to advance research through 2028. Stoke will receive an upfront payment of $165 million, with the possibility of additional milestone payments and royalties. Early trial results have shown promising reductions in seizures and cognitive improvements, offering hope for a breakthrough in treating Dravet syndrome at its genetic root. If successful, zorevunersen could be the first therapy to modify the disease rather than just manage symptoms, marking a significant step forward for the rare disease community.